Neuropathy and pain in Fabry disease

Abstract

Fabry disease (FD) is a multiorgan lysosomal storage disorder caused by mutations in the alfa-galactosidase A (GLA) gene. Pathogenic GLA mutations lead to impaired or even lost enzyme activity, which causes the accumulation of sphingolipids, e.g., globotriaosylceramide, in cells and tissues. The majority of FD patients experience triggerable pain, mainly acral and burning, which often begins in early childhood. While small fiber pathology is assumed to be the basis of FD pain, the underlying molecular mechanisms are not well understood. This review summarizes the clinical characteristics of neuropathy and neuropathic pain in FD, presents current treatment options, and gives an overview of the latest findings from experimental and human model systems on the pathomechanisms contributing to small fiber pathology and FD-associated pain.

Keywords

Fabry disease / small fiber neuropathy / FD-associated pain

References

[1] Platt FM,Davidson BL,Tifft CJ.Lysosomal storage diseases.Nat Rev Dis Primers2018;4:27

[2] Saito S,Sakuraba H.Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase a structures in Fabry disease.J Hum Genet2011;56:467-8

[3] Effraimidis G,Dunoe M.Systematic cascade screening in the Danish Fabry disease centre: 20 years of a national single-centre experience.PLoS One2022;17:e0277767 PMCID:PMC9668118

[4] Bertoldi G,Driussi G.Biochemical mechanisms beyond glycosphingolipid accumulation in Fabry disease: might they provide additional therapeutic treatments?.J Clin Med2023;12:2063 PMCID:PMC10004377

[5] Izhar R,La Russa A.Fabry disease in women: genetic basis, available biomarkers, and clinical manifestations.Genes2023;15:37 PMCID:PMC10815601

[6] Faro DC,Rodolico MS.Sex differences in anderson-Fabry cardiomyopathy: clinical, genetic, and imaging analysis in women.Genes2023;14:1804 PMCID:PMC10531426

[7] Eng CM,Gordon RE.A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.Am J Hum Genet2001;68:711-22 PMCID:PMC1274483

[8] Schiffmann R,Austin HA 3rd.Enzyme replacement therapy in Fabry disease: a randomized controlled trial.JAMA2001;285:2743-9

[9] Germain DP,Nicholls K.Treatment of Fabry's disease with the pharmacologic chaperone migalastat.N Engl J Med2016;375:545-55

[10] Li Q,Tian M.Clinical features and enzyme replacement therapy in 10 children with Fabry disease.Front Pediatr2023;11:1084336 PMCID:PMC9936091

[11] Morand O,Walter J.Symptoms and quality of life in patients with Fabry disease: results from an international patient survey.Adv Ther2019;36:2866-80 PMCID:PMC6822826

[12] Politei JM,Schenone AB.Small Fiber neuropathy in Fabry disease: a review of pathophysiology and treatment.J Inborn Errors Metab Scr2016;4:232640981666135

[13] Üçeyler N,Kramer D.Impaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control study.BMC Neurol2013;13:47 PMCID:PMC3672069

[14] Scott LJ,Luciano C.Quantitative analysis of epidermal innervation in Fabry disease.Neurology1999;52:1249-54

[15] Üçeyler N,Schönfeld D.Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.J Peripher Nerv Syst2011;16:304-14

[16] Arnold R,Issar T.Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease.Nephrol Dial Transplant2022;37:713-9

[17] Burlina AP,Politei JM.Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.BMC Neurol2011;11:61 PMCID:PMC3126707

[18] Schiffmann R,Dambrosia JM.Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.Muscle Nerve2003;28:703-10

[19] Maag R,Maier C.Detection of a characteristic painful neuropathy in Fabry disease: a pilot study.Pain Med2008;9:1217-23

[20] Hilz MJ.Evaluation of peripheral and autonomic nerve function in Fabry disease.Acta Paediatr Suppl2002;91:38-42

[21] Møller AT,Feldt-Rasmussen U.Autonomic skin responses in females with Fabry disease.J Peripher Nerv Syst2009;14:159-64

[22] Dutra-Clarke M,Curtin E.Variable clinical features of patients with Fabry disease and outcome of enzyme replacement therapy.Mol Genet Metab Rep2021;26:100700 PMCID:PMC7788237

[23] Bar N,Kiser K,Zar-Kessler C.Gastrointestinal sensory neuropathy and dysmotility in Fabry disease: presentations and effect on patient's quality of life.Clin Transl Gastroenterol2023;14:e00633 PMCID:PMC10749702

[24] Hopkin RJ,Banikazemi M.Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry.Pediatr Res2008;64:550-5

[25] Burand AJ Jr.Fabry disease pain: patient and preclinical parallels.Pain2021;162:1305-21 PMCID:PMC8054551

[26] Winter Y,Beuschlein F.Screening for health-related quality of life and its determinants in Fabry disease: a cross-sectional multicenter study.Mol Genet Metab2023;140:107692

[27] Körver S,Hollak CEM.Depressive symptoms in Fabry disease: the importance of coping, subjective health perception and pain.Orphanet J Rare Dis2020;15:28 PMCID:PMC6986064

[28] Radulescu D,Militaru V.Gastrointestinal manifestations and treatment options in Fabry disease patients. a systematic review.J Gastrointestin Liver Dis2022;31:98-106

[29] Üçeyler N,Kramer D.Characterization of pain in Fabry disease.Clin J Pain2014;30:915-20

[30] Rosa Neto NS, Bento JCB, Caparbo VF, Pereira RMR. Increased serum interleukin-6 and tumor necrosis factor alpha levels in fabry disease: correlation with disease burden.Clinics2021;76:e2643 PMCID:PMC8266164

[31] Laffer B,Ehlers-Jeske E,Brand E.Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.Front Immunol2024;15:1307558 PMCID:PMC10830671

[32] Üçeyler N,Mayer C,Held M.Tumor necrosis factor-α links heat and inflammation with Fabry pain.Mol Genet Metab2019;127:200-6

[33] Aerts JM,Kuiper S.Elevated globotriaosylsphingosine is a hallmark of Fabry disease.Proc Natl Acad Sci USA2008;105:2812-7 PMCID:PMC2268542

[34] Choi L,Kopach O.The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain.Neurosci Lett2015;594:163-8 PMCID:PMC4411215

[35] Nowak A,Sivasubramaniam V,Warnock DG.Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.J Med Genet2022;59:287-93 PMCID:PMC8867289

[36] Bichet DG,Auray-Blais C.Assessment of plasma lyso-Gb₃ for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease.Genet Med2021;23:192-201 PMCID:PMC7790748

[37] de Greef BT,Wolters EE.No Fabry disease in patients presenting with isolated small fiber neuropathy.PLoS One2016;11:e0148316 PMCID:PMC4750945

[38] Magg B,Wiedmann S,Sommer C.Self-administered version of the Fabry-associated pain questionnaire for adult patients.Orphanet J Rare Dis2015;10:113 PMCID:PMC4573689

[39] Üçeyler N,Thomas P,Heuschmann P.A comprehensive Fabry-related pain questionnaire for adult patients.Pain2014;155:2301-5

[40] Interdisziplinäre leitlinie für die diagnose und therapie des morbus Fabry. 2022. Available from: https://dgn.org/leitlinie/interdisziplinare-leitlinie-fur-die-diagnose-und-therapie-des-morbus-fabry [Last accessed on 2 Jul 2024]

[41] Ezgu F,Bicik Bahcebasi Z.Expert opinion on the recognition, diagnosis and management of children and adults with Fabry disease: a multidisciplinary Turkey perspective.Orphanet J Rare Dis2022;17:90 PMCID:PMC8889663

[42] Wanner C,Baron R.European expert consensus statement on therapeutic goals in Fabry disease.Mol Genet Metab2018;124:189-203

[43] Müntze J,Cybulla M.Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: a prospective, multicenter study.Mol Genet Metab2023;138:106981

[44] Hopkin RJ,Jefferies JL.Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry registry.Mol Genet Metab2023;138:106967

[45] Hilz MJ,Marthol H,Dütsch M.Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy.Neurology2004;62:1066-72

[46] Sasa H,Kino K.Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing surveillance in Japan.Mol Genet Metab2019;126:448-59

[47] Lenders M,Kurschat C.Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).Eur Heart J Cardiovasc Pharmacother2022;8:272-81

[48] Riccio E,Ferreri L.Switch from enzyme replacement therapy to oral chaperone migalastat for treating Fabry disease: real-life data.Eur J Hum Genet2020;28:1662-8 PMCID:PMC7784987

[49] Lee K,Zhang K.A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.Glycobiology2003;13:305-13

[50] Hoffmann B,Mehta A,Widmer U.FOS European InvestigatorsEffects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).J Med Genet2005;42:247-52

[51] Sergi B,Paludetti G.Inner ear involvement in Anderson-Fabry disease: long-term follow-up during enzyme replacement therapy. Acta Otorhinolaryngol Ital 2010;30:87-93. PMCID:PMC2882147

[52] Hughes DA,Hollak CE,Deegan PB.Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS-the Fabry outcome survey.Mol Genet Metab2011;103:207-14

[53] Tsuboi K.Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.BMC Pharmacol Toxicol2017;18:43 PMCID:PMC5463328

[54] Germain DP,Hughes DA.Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase a activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.Orphanet J Rare Dis2012;7:91 PMCID:PMC3527132

[55] Hughes DA,Shankar SP.Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.J Med Genet2017;54:288-96

[56] Finnerup NB,Haroutounian S.Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.Lancet Neurol2015;14:162-73

[57] Politei JM,Germain DP.Pain in Fabry disease: practical recommendations for diagnosis and treatment.CNS Neurosci Ther2016;22:568-76 PMCID:PMC5071655

[58] Ohshima T,Swaim WD.α-galactosidase a deficient mice: a model of Fabry disease.Proc Natl Acad Sci USA1997;94:2540-4 PMCID:PMC20124

[59] Hofmann L,Grießhammer A.Characterization of small fiber pathology in a mouse model of Fabry disease.Elife2018;7:e39300 PMCID:PMC6255391

[60] Spitzel M,Breyer M.Dysregulation of immune response mediators and pain-related ion channels is associated with pain-like behavior in the GLA KO mouse model of Fabry disease.Cells2022;11:1730 PMCID:PMC9179379

[61] Choconta JL,Dumbraveanu C,Kummer KK.Age-related neuroimmune signatures in dorsal root ganglia of a Fabry disease mouse model.Immun Ageing2023;20:22 PMCID:PMC10176851

[62] Lakomá J,Ferrer Montiel A,Liguori R.Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model.Mol Pain2016;12:174480691666372 PMCID:PMC5009828

[63] Waltz TB,Sadler KE.Sensory-specific peripheral nerve pathology in a rat model of Fabry disease.Neurobiol Pain2021;10:100074 PMCID:PMC8437817

[64] Miller JJ,Moehring F.Neuropathic pain in a Fabry disease rat model.JCI Insight2018;3:99171 PMCID:PMC5926911

[65] Talagas M,Leschiera R.Keratinocytes communicate with sensory neurons via synaptic-like contacts.Ann Neurol2020;88:1205-19

[66] Mikesell AR,Schulte ML.Keratinocyte piezo1 drives paclitaxel-induced mechanical hypersensitivity. bioRxiv 2023. PMCID:PMC10760029

[67] Erbacher C,Dinkel P.Interaction of human keratinocytes and nerve fiber terminals at the neuro-cutaneous unit.Elife2024;13:e77761 PMCID:PMC10791129

[68] Waltz TB,Prodoehl EK.Schwann cell release of p11 induces sensory neuron hyperactivity in Fabry disease. bioRxiv 2023. PMCID:PMC10245981

[69] Yogasundaram H,Putko BN.Elevated inflammatory plasma biomarkers in patients with Fabry disease: a critical link to heart failure with preserved ejection fraction. J Am Heart Assoc 2018;7:e009098. PMCID:PMC6404196

[70] Kanack AJ,Tiemeyer M.Platelet and myeloid cell phenotypes in a rat model of Fabry disease.FASEB J2021;35:e21818 PMCID:PMC8341388

[71] Willemen HLDM,Broeks M.Inflammation-induced mitochondrial and metabolic disturbances in sensory neurons control the switch from acute to chronic pain.Cell Rep Med2023;4:101265 PMCID:PMC10694662

[72] van der Vlist M,Willemen HLDM.Macrophages transfer mitochondria to sensory neurons to resolve inflammatory pain.Neuron2022;110:613-26.e9

[73] Palada V,Hugo A,Svensson CI.Expression of mitochondrial TSPO and FAM173B is associated with inflammation and symptoms in patients with painful knee osteoarthritis.Rheumatology2021;60:1724-33 PMCID:PMC8023995

[74] Chévrier M,Céline L.Autophagosome maturation is impaired in Fabry disease.Autophagy2010;6:589-99

[75] Ivanova MM,Iaonou C.Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.PLoS One2019;14:e0210617 PMCID:PMC6329517

[76] Marenco M,Sacchetti M,Giovannetti F.Autophagy-lysosome pathway alteration in ocular surface manifestations in Fabry disease patients.Orphanet J Rare Dis2022;17:291 PMCID:PMC9308246

[77] Nelson MP,O'Quinn DB.Autophagy-lysosome pathway associated neuropathology and axonal degeneration in the brains of alpha-galactosidase a-deficient mice.Acta Neuropathol Commun2014;2:20 PMCID:PMC3933238

[78] Chen H,Xie K.Effect of autophagy on allodynia, hyperalgesia and astrocyte activation in a rat model of neuropathic pain.Int J Mol Med2018;42:2009-19 PMCID:PMC6108883

[79] Liu K,Zhou F,Shi L.Inhibition of PI3K/AKT/mTOR signaling pathway promotes autophagy and relieves hyperalgesia in diabetic rats.Neuroreport2020;31:644-9

[80] Zhang E,Ko Y.Expression of LC3 and Beclin 1 in the spinal dorsal horn following spinal nerve ligation-induced neuropathic pain.Brain Res2013;1519:31-9

[81] Chen W.Upregulated TLR3 promotes neuropathic pain by regulating autophagy in rat with L5 spinal nerve ligation model.Neurochem Res2017;42:634-43

[82] Hehlert P,Göpfert MC.Drosophila mechanosensory transduction.Trends Neurosci2021;44:323-35

[83] Petersen M,Hoyer N,Soba P.Assaying thermo-nociceptive behavior in drosophila larvae.Bio Protoc2018;8:e2737 PMCID:PMC8203888

[84] Jang W,Cho EH,Kim C.Drosophila pain sensitization and modulation unveiled by a novel pain model and analgesic drugs.PLoS One2023;18:e0281874 PMCID:PMC9934396

[85] Braunstein H,Maor G,Rolfs A.Misfolding of lysosomal α-galactosidase a in a fly model and its alleviation by the pharmacological chaperone migalastat.Int J Mol Sci2020;21:7397 PMCID:PMC7583893

[86] Bonan CD.Editorial: zebrafish as a model for pharmacological and toxicological research.Front Pharmacol2022;13:976970 PMCID:PMC9393701

[87] Lopez-Luna J,Al-Nuaimy W.Impact of analgesic drugs on the behavioural responses of larval zebrafish to potentially noxious temperatures.Appl Anim Behav Sci2017;188:97-105

[88] Prober DA,Myers BR.Zebrafish TRPA1 channels are required for chemosensation but not for thermosensation or mechanosensory hair cell function.J Neurosci2008;28:10102-10

[89] Magalhães FEA,Santos SAAR.Adult zebrafish (danio rerio): an alternative behavioral model of formalin-induced nociception.Zebrafish2017;14:422-9

[90] Costa FV,Quadros VA,Kalueff AV.Understanding nociception-related phenotypes in adult zebrafish: behavioral and pharmacological characterization using a new acetic acid model.Behav Brain Res2019;359:570-8

[91] Elsaid HOA,Blomqvist M.Reduced α-galactosidase a activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype.Mol Genet Metab Rep2022;31:100851 PMCID:PMC8857658

[92] Klein T,Breyer M..Small fibre neuropathy in Fabry disease: a human-derived neuronal in vitro disease model. bioRxiv 2023.

[93] Kaneski CR,Schueler Hoffman UH.Generation of an in vitro model for peripheral neuropathy in Fabry disease using CRISPR-Cas9 in the nociceptive dorsal root ganglion cell line 50B11.Mol Genet Metab Rep2022;31:100871 PMCID:PMC9248215

[94] Kaneski CR,Schueler Hoffman UH.Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease.Mol Genet Metab Rep2022;33:100914 PMCID:PMC9449667

[95] Klein T,Breyer M.Small fibre neuropathy in Fabry disease: a human-derived neuronal in vitro disease model and pilot data.Brain Commun2024;6:fcae095 PMCID:PMC11024803

[96] Breyer M,Klein A.In vitro characterization of cells derived from a patient with the GLA variant c.376A>G (p.S126G) highlights a non-pathogenic role in Fabry disease.Mol Genet Metab Rep2024;38:101029 PMCID:PMC10926200

[97] DeCicco-Skinner KL,Cataisson C.Endothelial cell tube formation assay for the in vitro study of angiogenesis.J Vis Exp2014;91:e51312

[98] Do HS,Im I.Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.EBioMedicine2020;52:102633 PMCID:PMC6992938

[99] Klug K,Hans C.Endothelial cell dysfunction and hypoxia as potential mediators of pain in Fabry disease: a human-murine translational approach.Int J Mol Sci2023;24:15422 PMCID:PMC10607880

[100] Shen JS,Moore DF.Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.Mol Genet Metab2008;95:163-8 PMCID:PMC2593623

[101] Pollmann S,Manikowski D,Brand E.Endothelial dysfunction in Fabry disease is related to glycocalyx degradation.Front Immunol2021;12:789142 PMCID:PMC8670230

[102] Choi S,Na HY.Globotriaosylceramide induces lysosomal degradation of endothelial KCa_3.1 in Fabry disease.Arterioscler Thromb Vasc Biol2014;34:81-9

[103] Liu PW,Werley CA.A phenotypic screening platform for chronic pain therapeutics using all-optical electrophysiology.Pain2024;165:922-40 PMCID:PMC10950549

[104] Namer B,Eberhardt E.Pain relief in a neuropathy patient by lacosamide: Proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors.EBioMedicine2019;39:401-8 PMCID:PMC6354557